Clinical Trial Update: A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction [Phase 2]

View source ↗

Summary

Phase 2 open-label study reporting PK/PD properties of RUC-4 in patients with ST-elevation myocardial infarction (STEMI).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Disease
• Heart Diseases
• Myocardial Infarction
• St-elevation Myocardial Infarction

Drugs mentioned

• RUC-4

Snippet

Sponsor: CeleCor Therapeutics | Conditions: Coronary Disease, Myocardial Infarction | Phase 2 | Status: COMPLETED